Viridian Therapeutics, Inc. (0K1R.L)
USD 19.62
(-7.91%)
USD 19.62
(-7.91%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -254.45 Million USD | -89.46% |
| 2022 | -134.3 Million USD | -68.45% |
| 2021 | -79.72 Million USD | 27.77% |
| 2020 | -110.38 Million USD | -162.94% |
| 2019 | -41.97 Million USD | -26.89% |
| 2018 | -33.08 Million USD | -24.69% |
| 2017 | -26.53 Million USD | -112.12% |
| 2016 | -12.5 Million USD | -11.81% |
| 2015 | -11.18 Million USD | -62.91% |
| 2014 | -6.86 Million USD | -3399.77% |
| 2013 | -196.21 Thousand USD | 95.13% |
| 2012 | -4.02 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -55.89 Million USD | 21.8% |
| 2024 Q2 | -72.18 Million USD | -29.14% |
| 2023 Q2 | -59.27 Million USD | 18.21% |
| 2023 FY | -254.45 Million USD | -89.46% |
| 2023 Q3 | -51.22 Million USD | 13.58% |
| 2023 Q4 | -71.47 Million USD | -39.54% |
| 2023 Q1 | -72.47 Million USD | -47.71% |
| 2022 Q4 | -49.06 Million USD | -64.73% |
| 2022 Q2 | -29.56 Million USD | -14.2% |
| 2022 Q1 | -25.88 Million USD | 10.98% |
| 2022 FY | -134.3 Million USD | -68.45% |
| 2022 Q3 | -29.78 Million USD | -0.75% |
| 2021 Q2 | -17.99 Million USD | 2.79% |
| 2021 Q4 | -29.08 Million USD | -105.75% |
| 2021 FY | -79.72 Million USD | 27.77% |
| 2021 Q1 | -18.51 Million USD | 79.56% |
| 2021 Q3 | -14.13 Million USD | 21.47% |
| 2020 Q2 | -6.37 Million USD | 20.31% |
| 2020 Q3 | -5.41 Million USD | 15.12% |
| 2020 FY | -110.38 Million USD | -162.94% |
| 2020 Q4 | -90.59 Million USD | -1574.64% |
| 2020 Q1 | -7.99 Million USD | 20.58% |
| 2019 Q3 | -11.23 Million USD | -25.59% |
| 2019 Q1 | -11.73 Million USD | -12.27% |
| 2019 FY | -41.97 Million USD | -26.89% |
| 2019 Q4 | -10.07 Million USD | 10.32% |
| 2019 Q2 | -8.94 Million USD | 23.81% |
| 2018 FY | -33.08 Million USD | -24.69% |
| 2018 Q4 | -10.45 Million USD | -14.23% |
| 2018 Q3 | -9.15 Million USD | -3.27% |
| 2018 Q2 | -8.86 Million USD | -91.84% |
| 2018 Q1 | -4.61 Million USD | 27.31% |
| 2017 Q1 | -6.93 Million USD | -26.79% |
| 2017 Q2 | -7.35 Million USD | -5.92% |
| 2017 Q3 | -5.88 Million USD | 19.88% |
| 2017 Q4 | -6.35 Million USD | -7.9% |
| 2017 FY | -26.53 Million USD | -112.12% |
| 2016 FY | -12.5 Million USD | -11.81% |
| 2016 Q1 | -2.73 Million USD | 7.51% |
| 2016 Q2 | -2.48 Million USD | 9.18% |
| 2016 Q3 | -1.81 Million USD | 26.89% |
| 2016 Q4 | -5.47 Million USD | -201.38% |
| 2015 FY | -11.18 Million USD | -62.91% |
| 2015 Q4 | -2.95 Million USD | 5.47% |
| 2015 Q2 | -2.49 Million USD | 4.67% |
| 2015 Q1 | -2.61 Million USD | -15.79% |
| 2015 Q3 | -3.12 Million USD | -25.62% |
| 2014 Q4 | -2.25 Million USD | -38.14% |
| 2014 FY | -6.86 Million USD | -3399.77% |
| 2014 Q1 | -166.69 Thousand USD | -165.35% |
| 2014 Q2 | -2.81 Million USD | -1586.57% |
| 2014 Q3 | -1.63 Million USD | 41.91% |
| 2013 Q1 | -79.25 Thousand USD | 0.0% |
| 2013 FY | -196.21 Thousand USD | 95.13% |
| 2013 Q4 | 255.07 Thousand USD | 181.84% |
| 2013 Q3 | -311.65 Thousand USD | -416.22% |
| 2013 Q2 | -60.37 Thousand USD | 23.82% |
| 2012 FY | -4.02 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | -478.164% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | -24.121% |
| Codexis, Inc. | -68.06 Million USD | -273.812% |
| Organovo Holdings, Inc. | -15.08 Million USD | -1586.663% |